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Abstract 
Chimeric antigen receptors (CARs) combine T-cell activation with antibody-mediated 
tumor antigen specificity, bypassing the need for T-cell receptor (TCR) ligation. A 
limitation of CAR technology is on-target off-tumor toxicity caused by target antigen 
expression on normal cells.  Using GD2 as a model cancer antigen, we hypothesized 
that this could be minimized by using T cells expressing V9V2 TCR, which 
recognizes transformed cells in an MHC-unrestricted manner, in combination with a 
co-stimulatory CAR that would not bypass the TCR. 
An anti-GD2 CAR containing the endodomain of the NKG2D adaptor, DAP10 was 
expressed in V9V2+ T cells. Differential ligation of the CAR and/or TCR using 
antibody-coated beads showed that pro-inflammatory cytokine response depended 
on activation of both receptors. Moreover in killing assays, GD2-expressing 
neuroblastoma cells that engaged the Vγ9Vδ2 TCR were efficiently lysed whereas 
cells that express GD2 equivalently but do not engage the Vγ9Vδ2 TCR were 
untouched.  Differentiation between “X-on-tumor” and “X-off-tumor” offers potential 
for safer immunotherapy and broader target selection. 
 
Abbreviations 
TCR   T-cell receptor 
TCR   Gamma-delta T-cell receptor 
V9V2 or V2 V-gamma-9/V-delta22 gamma-delta T-cell receptor 
CAR   Chimeric antigen receptor 
CAR-T  cell  T-cell expressing a chimeric antigen receptor 
GD2-28- Chimeric antigen receptor targeting GD2, containing CD28 and 
CD3 endodomains 
GD2-DAP10 Chimeric antigen receptor targeting GD2, containing the 
DAP10 endodomain only 
IPP Isopentenyl-5-pyrophosphate 
ZOL Zoledronic acid 
 
Summary (max 40 words) 
T cells expressing chimeric antigen receptors (CARs) potently kill tumor cells 
expressing target antigen but are limited by on-target off-tumor toxicity. This proof-of-
concept paper describes a means of overcoming this toxicity by expressing co-
stimulatory CARs in T cells rather than T cells.  
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Introduction 
 
Chimeric antigen receptor (CAR)-based immunotherapeutics have been developed 
to harness the cytotoxic potential of peripheral blood T cells. CARs comprise 
ectodomains, which recognize tumor-associated antigens, fused to endodomains, 
which provide co-stimulatory signals. The majority of CARs currently under 
investigation contain the CD3 endodomain, which provides TCR signalling, in 
addition to one (second generation) or two (third generation) costimulatory 
endodomains such as CD28, 4-1BB or OX40 (Chmielewski et al., 2013).  When 
expressed in T cells, second and third generation CARs bypass the requirement 
for MHC-restricted antigen presentation, providing CD3-mediated TCR signalling 
and costimulatory signals in the presence of the target antigen. CAR+ T cells 
targeting CD19 have shown unprecedented clinical efficacy in lymphoid malignancy 
in adults and children (Maude et al., 2014; Lee et al., 2015). Progress in targeting 
solid tumors such as neuroblastoma has been more measured, though CAR+ T cells 
are attractive as they offer the potential for sustained anti-tumor immunity. CARs 
targeting GD2 in neuroblastoma have shown early promise (Pule et al., 2008; Louis 
et al., 2011) but the potential for sustained neurotoxicity remains a concern, 
especially given the severe toxicities encountered in other CAR+ T-cell trials as a 
result of unexpected off-tumor antigen expression (Lamers et al., 2006; Morgan et 
al., 2010).  As a means to overcome this limitation we have devised a CAR design in 
which signals 1 and 2 of T-cell activation are provided by separate receptors.    
 
GD2 is a ganglioside abundantly expressed on the surface of neuroblastoma cells 
and on several other cancer types.  It is a highly ranked tumor associated antigen 
and an attractive target for immunotherapy (Cheever et al., 2009).  In 2010, it was 
shown that adjuvant immunotherapy comprising an antibody (ch14.18-Sp2/0) 
targeting GD2, in combination with IL-2, GM-CSF and isotretinoin significantly 
improved the event-free and overall survival of high-risk neuroblastoma patients (Yu 
et al., 2010).  However, the neurotoxicity and long-term survival benefits of anti-GD2 
monoclonal antibody therapy are being questioned. The opiate requirements of 
patients receiving GD2-targeting antibody are substantial and a minority of patients 
develop long-term neurological sequelae (Yu et al., 2010; Simon et al., 2004). The 
degree of acute and chronic neurotoxicity that will emerge from ongoing trials using 
second and third generation GD2-targeting CARs is not yet known.  
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Comprising 1-5% of circulating T-cell numbers, T cells possess innate and 
adaptive immune functions. Their ability to recognize danger-associated molecular 
patterns to differentiate between healthy and tumor cells in an MHC-independent 
manner (Hayday, 2009) distinguishes them from T cells, which rely on MHC-
restricted antigen presentation to detect altered-self.  The most abundant T-cell 
subset in human peripheral blood expresses the V9V2 TCR (hereafter referred to 
as V2+ T cells), responding to increased phosphoantigen production in target cells 
(Vantourout and Hayday, 2013). Phosphoantigens such as isopentenyl-5-
pyrophosphate are cholesterol biosynthesis intermediates, and their accumulation in 
response to metabolic dysregulation has been linked to aberrant EGFR activity 
(Poupot and Fournié, 2004; Asslan et al., 1999).  Detection of phosphoantigen by the 
V9V2 TCR is indirect and, unlike antigen recognition by T cells, does not depend 
on MHC presented epitopes.  Phosphoantigen detection is thought to occur through 
its binding to butyrophilin-3A1, although the mechanism by which TCR engagement 
is effected is a matter of intense debate, and other models have been proposed 
(Vavassori et al., 2013; Harly et al., 2012; Sandstrom et al., 2014; Silva-Santos et al., 
2015).   
 
TCR engagement alone is insufficient to induce V2+ T-cell cytotoxicity against 
neuroblastoma. A second signal is required, much in the same way that T cells 
require a costimulatory signal.  Costimulation of T cells is known to occur in part 
through receptors such as NKG2D which are ligated by danger-associated molecules 
such as MIC-A and MIC-B, but can also be provided via Fc receptors within the 
context of an opsonized target cell as we have previously shown (Fisher et al.; 2014). 
Neuroblastoma cells have been reported to evade NKG2D-mediated immune 
destruction through down-regulation of NKG2D ligands or by secretion of receptor-
blocking soluble ligands (Nedellec et al., 2010; Raffaghello et al., 2004). This has 
been demonstrated to be an important escape mechanism against NK cell-mediated 
killing of neuroblastoma (Raffaghello et al., 2005). Therefore, the NKG2D-adaptor 
protein, DAP10, was an attractive candidate for inclusion in a costimulatory CAR 
designed to target neuroblastoma. This approach is a development of previously 
reported strategies which divided the CD3 and co-stimulatory signals between two 
CARs targeting different tumor associated antigens (Lanitis et al., 2013; Kloss et al., 
2013).  By using the pre-existing danger-sensing specificity of the TCR, it is 
possible to escape the requirement for two distinct tumor associated antigens. 
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In this report we demonstrate that V2+ T cells are amenable to manipulation with a 
chimeric antigen receptor comprising a conventional ectodomain to target GD2 linked 
to an endodomain that provides DAP10 costimulation but no TCR signal. This design 
supplements but does not replace the endogenous TCR signal, capitalizing on the 
innate ability of T cells to differentiate between healthy and transformed self in an 
MHC-independent manner.  Thus, “costimulation-only” CARs provide cytotoxic 
activation on encountering a cancer cell but not upon encountering non-transformed 
cells expressing the same target antigen.   
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Materials and methods 
 
Isolation of PBMCs and T-cell expansion 
20 ml of whole blood were diluted with 10 ml PBS + 500 μl 100 mM EDTA and 
layered on 20 ml Percoll. Interface PBMCs (20 min, 300xg, RT) were washed in PBS 
and re-suspended in 25 ml T-cell medium (RPMI-1640 medium supplemented with L-
glutamine (2 mM, Sigma-Aldrich (Missouri, USA)), penicillin/streptomycin (100 IU/ml 
penicillin, 100 μg/ml streptomycin (Sigma-Aldrich)) and 10% FCS (v/v, (Gibco, 
Massachusetts, USA)). In some experiments CD56+ cells were depleted from PBMC 
preparations (day 1) by positive selection using CD56 MicroBeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Depletions to less than 3% of CD56+ cells were 
achieved regularly. For γδ T-cell expansion, 5 μM zoledronic acid (Actavis, New 
Jersey, USA) and 100 IU/ml IL-2 (Aldesleukin, Novartis, Frimley, UK) was added to 
PBMC suspension after PBMC isolation (day 1). IL-2 was replenished every 2-3 days 
by removing half of the media from the well and replacing with fresh media 
containing 200 IU/ml IL-2. αβ T-cell expansion was induced by addition of anti-
CD3/CD28 Dynabeads (Gibco, Massachusetts, USA). 
 
Construction of retroviral constructs  
The retroviral vector used in all constructs was the splicing oncoretroviral vector SFG 
(Rivière et al., 1995), pseudotyped with an RD114 envelope. DNA fragments were 
amplified using the Phusion HT II polymerase according to the manufacturer’s 
instructions (Thermo Scientific, Massachusetts, USA). PCR was carried out in a 
PTC-200 DNA Engine (MJ Research, Massachusetts, USA). PCR products were 
extracted from 1% agarose gels using the Wizard SV Gel & PCR Clean-Up kit 
(Promega, Wisconsin, USA). Sample concentrations were determined using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Massachusetts, USA).  
The CAR ectodomain comprised an scFv against human GD2 and a spacer derived 
from the human IgG4 CH2-CH3 portion has been described before in third 
generation format  (Thomas et al., 2016) .  The endodomain was generated using 
oligo-assembly PCR based on a codon optimised sequence of the human DAP10 
endodomain (NCBI Gene ID 10870).  In addition to the CAR construct, RQR8 which 
is a marker bearing a CD34 epitope (Philip et al., 2014) was included, separated 
from the CAR by a cleavable 2A peptide.  This allows CAR expressing cells to be 
detected by flow cytometry by staining using the anti-CD34 antibody clone QBend10. 
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Production of viral particles by transfection  
1.5x106 293T cells/100 mm2 dish (Nunclon Delta Surface, Thermo Fisher) were 
plated at day 1 in 293T medium (D-MEM, 10 % FCS (v/v)). γ-retroviral particles were 
produced by co-transfection of 293T cells at day 2 using GeneJuice Transfection 
Reagent (Novagen/Millipore, Massachusetts, USA) in accordance with 
manufacturer’s directions. Viral particle-containing supernatants were harvested at 
day 4; medium was replenished, and harvested at day 5. Supernatants were pooled, 
filtered (0.45-μm filter, Millipore) and directly used for transductions or stored at  
-80°C.   
 
Transduction of T cells 
Transduction of T cells was carried out in Retronectin (Takara Bio, Tokyo, Japan) 
coated 24-well plates, which were pre-loaded with viral supernatant.  0.5x106 T cells 
suspended in 0.5 ml T-cell medium + 400 IU IL-2 were combined with 1.5 ml viral 
supernatant and centrifuged for 40 min, 1000xg at RT.   Timing of transduction 
differed between T cells and T cells due to expansion dynamics.  T-cell 
expansion was stimulated with 5 μM zoledronic acid (Actavis, New Jersey, USA) and 
100 IU/ml IL-2 (Aldesleukin,) and transduction performed at day 5.  At day 8 of 
culture (day 3 after transduction) cells were pooled, washed and plated at 2x106 
cells/ml in T-cell medium + 100 IU IL-2/ml (24-well plates, Nunclon Delta Surface, 
Thermo Scientific, Massachusetts, USA). Transduction efficiency was determined by 
flow cytometry at day 10 (day 5 after transduction).  In the case of αβ T cells, 
transduction was performed 72 h following stimulation with anti-CD3/CD28 
Dynabeads (Gibco, Massachusetts, USA) in the presence of 100 IU/ml IL-2 
(Aldesleukin), with re-plating 3 days after transduction. 
 
Flow cytometry 
For the analysis of intracellular cytokines, cells were incubated for 4 hours in T-cell 
medium supplemented with 1x 5 μg/ml Brefeldin A (BioLegend, California, USA). For 
exclusion of dead cells the Zombie Yellow Fixable Viability Kit (BioLegend) was 
used. For Fc-receptor blocking, cells were incubated in PBS supplemented with FcR 
Blocking Reagent (Miltenyi Biotec). For intracellular staining of cytokines the Inside 
Stain Kit (Miltenyi Biotec) was used. For absolute cell counting in secondary 
expansion experiments CountBright beads (Molecular Probes/Life Technologies, 
California, USA) were applied. The following antibodies were used to perform 
analysis by flow cytometry: anti-CD3-biotin (OKT3), anti-CD3-BV785 (OKT3), anti-
CD3-APC (UCHT1), anti-CD56-FITC (HCD56), anti-CD69-APC-Cy (FN50), anti-
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CD279/PD-1-APC-Cy7 (EH12.2H7), anti-CD366/Tim-3-PE-Cy7 (F38-2E2), anti-TCR 
Vδ2-PE (B6), anti-TCR αβ-APC (IP26), anti-IFN-γ-FITC (4S.B3), anti-TNF-α-BV711 
(MAb11), anti-GD2-PE (14G2a) from BioLegend, anti-CD34-APC (QBEnd10) from 
R&D Systems (Minnesota, USA), anti-CD25-FITC (M-A251) from BD Pharmingen 
(San Jose, California, USA). 
 
51Cr-killing assay 
To assess the killing capacity of T cells, 5,000 51Cr-labelled target cells were co-
cultured with 50,000, 25,000, 12,500 or 6,250 effector cells in 200 μl T-cell medium + 
100 IU IL-2/ml. Cells were incubated in 96-well V-bottomed plates (Greiner Bio-one, 
Kremsmünster, Austria) for 4 h. 50 μl of supernatant were transferred into Isoplate-96 
HB plates (PerkinElmer, Massachusetts, USA). After addition of 150 μl scintillation 
cocktail (Optiphase Supermix, PerkinElmer) samples were incubated overnight at 
RT. Counts were acquired using a 1450 MicroBeta TriLux scintillation counter 
(PerkinElmer). 
  
Activation of T cells using antibody-coated beads 
Anti-Biotin MACS iBeads (Miltenyi, Biotec) were labelled with 10 μg anti-CD3-biotin 
(OKT3, BioLegend), 10 μg anti-IgG (Fc)-biotin (Novex/Life Technologies), or 10 μg of 
anti-CD3-biotin and 10 μg anti-IgG (Fc)-biotin, respectively. After incubation (10 min, 
4°C), beads were washed twice with PBS and re-suspended in T-cell medium. To 
assess T-cell functionality and act as a positive control, anti-CD3/CD28 Dynabeads 
were re-suspended in T-cell medium as well. Bead suspensions (100 μl) were plated 
in 96-well U-bottom plates (Thermo Scientific). Effector T-cell preparations were 
added (0.2x106 cells/well in 100 μl T-cell medium) and incubated with beads for 24 h. 
No exogenous IL-2 was added to the medium in either case.  After 23 h 100 μl of 
supernatant were harvested for analysis of cytokine secretion by Cytometric Bead 
Array (CBA) and intracellular cytokine staining, i.e. data generated by CBA and 
intracellular cytokine staining are from the same experiments and are based on the 
same sample size. 
 
Cytokine secretion assay 
The BD CBA Flex Set Cytometric Bead Array (Becton Dickinson, New Jersey, USA) 
was used in accordance with manufacturers instructions to measure the 
concentrations of cytokines including IL-2, IL-4, IL-10, IL-17a, TNF-, IFN- and 
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Granzyme B in the supernatant of T cells stimulated for 23 h with antibody-coated 
beads as above.    
 
Secondary expansion of transduced cells following antigen challenge 
T cells that had been transduced to express the GD2-DAP10 CAR were 
maintained for 3 weeks following transduction in T-cell medium and 100 IU/ml IL-2 
(Aldesleukin).  Following the 3-week culture with no further TCR stimulus, the T 
cells were co-cultured with irradiated (60 Gy) neuroblastoma cell lines (LAN-1 or SK-
N-SH) at a 1:1 effector:target (E:T) ratio.  Live cell numbers were determined using 
Trypan blue exclusion and the number of live TCRV2+/CAR+ T cells was 
determined by flow cytometry using the Zombie Yellow fixable viability dye 
(Biolegend) in addition to staining for TCR V2 and the CD34 epitope which is co-
expressed with the CAR.  By multiplying the number of live cells by the percentage of 
live cells that were TCRV2+/CAR+ the absolute cell number could be determined 
and used to calculate a fold change based on the starting cell number. 
 
Cell lines 
Human neuroblastoma cells lines Kelly, SK-N-SH and LAN-1, and the murine colonic 
carcinoma cell line CT26 were originally obtained from the ATCC. The Ewing’s 
sarcoma cell line TC-71 was obtained from DSMZ (Braunschweig, Germany).   
CT26-GD2 cells were generated by transducing wild-type CT26 with SFG 
gammaretrovirus encoding GD2 and GD3 synthase co-expressed via foot and mouth 
virus 2A self-cleaving peptide sequence, kindly provided by M Pule (UCL). After 
transduction, single GD2-expressing clones were generated by limiting dilution, and 
expanded.  
Statistical analysis 
Analyses were performed using GraphPad Prism version 6.0 (GraphPad, California, 
USA).  In instances where comparison was made between two groups with one 
variable only, a t-test was used. Comparisons of more than two groups defined by 
one factor were done by 1-way ANOVA followed by Bonferroni post-hoc analysis. For 
comparisons of conditions where there was more than one variable (for example E:T 
ratio and transductions status) a 2-way ANOVA with Bonferroni correction was used 
to determine statistical significance. These results were deemed to be statistically 
significant if P<0.05.  Where applicable, the following notation is used to denote 
significance:  *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.   
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Supplementary Figures 
In order to determine that the bead-based stimulation of cells would provide reliable 
and consistent stimulation we confirmed that staining by a directly fluorochrome-
conjugated anti-CD3 or anti-Fc antibody gave equivalent results to a biotinylated 
antibody used in conjunction with fluorochrome conjugated streptavidin 
(Supplementary Figure S1), and that the anti-biotin bead binding to biotinylated 
antibody did not interfere with streptavidin binding to the same antibody 
(Supplementary Figure S2).   Supplementary figures S3-S5 provide more detail on 
the exhaustion and activation phenotype of GD2-DAP10 and GD2-28- transduced 
V2+ T cells. Supplementary Figure S3 shows differential expression of PD-1 which 
is significantly higher in transduced cells compared to non-transduced, and at day 16 
was significantly lower in GD2-DAP10 CAR+ V2+ T cells compared to GD2-28- 
expressing T cells or V2+ T cells.  Supplementary Figure S4 shows an 
additional time point in the overall analysis of exhaustion phenotype.  Supplementary 
Figure S5 summarizes data on cellular activation in order to further characterize the 
T-cell phenotype after expansion and transduction. 
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Results 
  
Second generation CARs override the requirement of V2+ T cells for a 
second signal to induce cytotoxicity against neuroblastoma. 
 
V2+ T cells are the most common subtype in human blood and are capable of 
direct interaction with tumor cells through the Vγ9Vδ2 TCR. However, we have 
previously demonstrated that V2+ T cells are incapable of significant direct 
cytotoxicity against neuroblastoma cell lines although capable of antibody-dependent 
killing following addition of an antibody recognizing GD2, which is brightly expressed 
on neuroblastoma. The degree of antibody-dependent cell-mediated cytotoxicity 
(ADCC) was proportional to the degree of antigen-antibody-CD16 interaction (Fisher 
et al.; 2014). To overcome this antibody dependence we expressed a second 
generation anti-GD2 CAR containing CD3 and CD28 endodomains (GD2-28-, 
Figure 1A) in V2+ cells, and compared the antibody-dependent and -independent 
killing of GD2+ and GD2- neuroblastoma cell lines.  CARs were developed to bypass 
the need for TCR and costimulatory molecule engagement in T-cell immunotherapy, 
and will signal in the absence of a TCR ligand as shown in Figure 1A.  Expression of 
GD2-28- in the V2+ T cells was associated with increased antibody independent 
cytotoxicity (Figure 1B) against GD2+ cell lines (Figure 1B & 1C). The benefit of CAR 
expression on T-cell cytotoxicity was highly significant (Figure 1C) indicating that 
CAR expression of zoledronate expanded V2+ is capable of transducing cytotoxic 
signals in these cells.  It should be noted that the transduction efficiency and duration 
of stimulation differs between zoledronic acid induced CAR+ T cells and the CAR+ 
T cells stimulated with anti-CD3/28 beads.  Therefore comparison of relative 
cytotoxic potential of these populations cannot be inferred from this experiment. 
 
Specific and selective activation of GD2-DAP10 CAR-expressing γδT cells 
 
We speculated that it might be possible to retain full signal 2-dependent killing of 
neuroblastoma by V2+ cells whilst avoiding killing of non-transformed GD2-
expressing cells by exploiting the ability of the Vγ9Vδ2 TCR to provide signal 1 
following engagement by stressed but not by non-stressed cells. To this end we 
generated a chimeric antigen receptor comprising GD2-binding ectodomain and an 
endodomain containing the DAP10 endodomain hereafter referred to as GD2-DAP10 
(Figure 2A).  The DAP10 endodomain was chosen because DAP10 is the signalling 
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adaptor protein for NKG2D, an important activatory receptor found on NK cells and 
T cells and because neuroblastoma is known to demonstrate immune evasion 
through blockade of NKG2D signalling (Nedellec et al., 2010; Raffaghello et al., 
2004). 
 
To investigate the specific activation of GD2-DAP10 CAR+ γδT cells in comparison to 
GD2-28-ζ CAR+ γδT cells without the influence of additional confounding factors we 
established an in vitro assay using antibody coated anti-biotin beads (Supplementary 
Figures S1 and S2). These beads were labelled with biotinylated anti-CD3 antibody 
to engage the Vγ9Vδ2 TCR and/or anti-CAR antibody to engage the CH2CH3 linker 
in the respective CARs (Figure 2B).  By coating the beads with only one of the two 
antibodies, TCR and CAR intracellular signals could be isolated from each other.  
Due to the changing presence or absence of either signal 1 or signal 2 in this system, 
differences in the cytokine production profile were expected between T cells 
expressing either the GD2-DAP10 or GD2-28-ζ CAR.  Intracellular cytokine 
production was assessed by flow cytometry  (Figure 2C) which demonstrated that, 
whilst stimulation of the CAR alone was sufficient to stimulate IFN- production in 
GD2-28- CAR+ V2+ T cells, CD3 and CAR stimulation was required to stimulate 
IFN- production in GD2-DAP10 CAR+ V2+ T cells.   
 
Incubation with unlabelled or anti-CD3 antibody-coated beads did not induce the 
production of IFN-γ in T cells transduced with either type of CAR. GD2-DAP10 
CAR+ V2+ cells showed increased production of IFN- compared to untransduced 
cells in the same culture when both the CAR and TCR were stimulated, consistent 
with both signals 1 and 2 being provided by the bead-stimulated receptors (Figure 
2D). In contrast, incubation with beads that only engaged the CAR did not induce 
IFN-γ production in GD2-DAP10 V2+ cells, i.e. when the TCR is not engaged. 
GD2-28-ζ CAR+ V2+ cells produced IFN-γ upon engagement of the CAR alone since 
both signals were provided by the CAR-endodomain structure. Hence, full IFN- 
response of GD2-DAP10 CAR+ γδT cells only when engagement of both the TCR for 
signal 1 and of the CAR for signal 2 is provided, but not following engagement of 
either the TCR or the CAR alone. Interestingly, TNF-α was produced in the GD2-
DAP10 CAR γδT following engagement of the CAR alone but not by engagement of 
the TCR indicating that the DAP10 derived signal 2 alone was sufficient to generate 
a TNF-α response (Figure 2E). 
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To further characterize T-cell function following ligation of either the GD2-DAP10 
CAR or the GD2-28- CAR we measured the concentration of cytokines in the 
supernatant following stimulation with beads as described above.  Release of IFN-, 
TNF-, IL-2, IL-4 and Granzyme B by GD2-DAP10 V2+ cells was only seen when 
both CD3 and the CAR were stimulated.  If CD3 or the CAR were stimulated in 
isolation, cytokine release was minimal or absent.  This was not the case for GD2-
28- V2+ cells which as expected produced substantial amounts of these cytokines 
following CAR ligation alone. Interestingly GD2-28- V2+ cells also produced IL-10 
following CAR stimulation, which was not seen in the GD2-DAP10 V2+ cells, even 
when CD3 and the CAR were stimulated (Figure 3).   
 
T cells expressing GD2-DAP10 CARs show cytotoxicity against GD2+ 
neuroblastoma and Ewing sarcoma in vitro 
   
To evaluate possible therapeutic efficacy of the GD2-DAP10 CAR in V2+ T cells 
we evaluated specific cytotoxicity against representative cell lines derived from the 
childhood cancers neuroblastoma and Ewing sarcoma, which we and others have 
previously demonstrated to express GD2 uniformly (Kailayangiri et al., 2012; Fisher 
et al. 2016). Expression of the GD2-DAP10 CAR in V2+ T cells yielded 
significantly enhanced cytotoxicity against the GD2+ neuroblastoma cell line LAN-1, 
which was equivalent to the cytotoxicity imparted by the GD2-28- CAR expressed in 
V2+ T cells (Figure 4A).  This effect was also seen against GD2+ Ewing sarcoma 
cell lines such as TC-71 (Figure 4B) but was not seen against GD2 non-expressing 
neuroblastoma cell line SK-N-SH (Figure 4C). To demonstrate that the GD2-DAP10 
CAR was not providing sufficient signal to elicit killing independently of the TCR we 
expressed the same construct in T cells.  Expression of the GD2-DAP10 CAR had 
no effect on T-cell cytotoxicity against GD2+ neuroblastoma cell lines unlike the 
conventional GD2-28- CAR which significantly enhanced T-cell cytotoxicity 
against LAN-1 GD2+ neuroblastoma cells (Figure 4D). 
 
T cells expressing GD2-DAP10 CARs do not show toxicity against GD2+ cells 
that do not engage the TCR 
 
Phosphoantigens such as isopentenyl-5-pyrophosphate (IPP) are produced in 
increased quantities by cancer cells and, in human cells, are detected by the V9V2 
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TCR via mechanisms involving intermediate molecules such as butyrophilin 
(Vavassori et al., 2013). This process has been linked to aberrant EGFR activity 
which is seen in many tumor types (Poupot and Fournié, 2004; Asslan et al., 1999).  
Healthy cells do not produce increased levels of phosphoantigen and therefore do 
not engage the TCR. When using GD2 as a model antigen, culture of “healthy” 
human GD2+ cells is not technically or ethically feasible, given that GD2 expression 
is restricted to peripheral neurons. MHC-independent phosphoantigen recognition by 
the V9V2 TCR is species-specific (Kato et al., 2003; Green et al., 2004); 
therefore we developed a murine model of a GD2+ cell line that would not engage the 
human V9V2 TCR by transducing the murine colon carcinoma cell line CT26 to 
express  GD2, as murine cells do not engage the human V9V2+ TCR  (Figure 5A)  
 
First, in order to demonstrate the suitability of the antigen model, we determined that 
the expression of GD2 alone was sufficient to increase the susceptibility of CT26 to 
killing by T cells expressing the GD2-28- CAR (Figure 5B).  V2+ T cells 
expressing the second generation GD2-28- CAR retained the ability to kill CT26-
GD2 cells; in contrast, GD2-DAP10 CAR+ V2+ T cells did not significantly kill 
CT26-GD2 cells, consistent with failure of TCR engagement and lack of the 
necessary signal 1 (Figure 5C). The killing by GD2-DAP10 CAR+ V2+ T cells was 
dependent on the presence of the target antigen because wild type CT26 elicited no 
killing response from these effectors (Figure 5C, right panel). Hence, just as lack of 
engagement of the TCR in GD2-DAP10 CAR+ V2 cells leads to failure of IFN-γ 
production in the bead-based system (Figure 2D), failure to engage the TCR by a 
cellular target, results in a failure to elicit cytotoxicity.   
 
T cells expressing GD2-DAP10 CARs have a favorable phenotype for 
adoptive transfer  
The ability to exert specific cytotoxicity against tumor cells must be accompanied by 
the ability to mount an antigen-specific secondary expansion of CAR+ T-cell 
populations.  Failure to do this has been linked to T-cell exhaustion and obstructs the 
efficacy of CAR-T cells used in clinical trials (Long et al., 2015).   Unfortunately, 
testing in-vivo persistence in animal models is complicated by the potential for a 
xeno-response to drive T-cell expansion, which would confound results.  Therefore 
an in-vitro model of rested CAR+ cells was used.  V2+ cells expressing the GD2-
DAP10 CAR which had been left for 3 weeks without antigenic challenge following 
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initial zoledronic acid stimulation were re-challenged with an irradiated GD2+ cell line 
(LAN-1) or a GD2- control (SK-N-SH) or simply maintained in a target-free state.  Co-
culture with the GD2+ neuroblastoma cell line LAN-1 led to a sustained secondary 
expansion over a 3-week period, whereas incubation with the GD2- neuroblastoma 
cell line SK-N-SH produced no significant difference from cells incubated with no 
targets (Figure 6A). 
 
T-cell exhaustion is associated with phenotypic and functional changes.  Exhausted 
T-cells are less able to mount a secondary expansion when challenged, and will 
express cell surface markers such as TIM-3 and PD-1. Exhaustion attenuates the 
response of adoptively transferred CAR-T and reduces their clinical efficacy, an 
effect which can be reduced through choice of CAR endodomain (Long et al., 2015).  
To determine the susceptibility of T cells expressing either GD2-28- CARs or 
GD2-DAP10 CARs to exhaustion we determined their expression of TIM-3 and PD-1 
over the course of a prolonged culture (Figure 6B). For the purposes of statistical 
analysis, “exhaustion” was defined as the expression of at least one of the markers 
TIM-3 and PD-1.  Expression of either CAR promoted a more exhausted phenotype, 
which was associated with greater PD-1 expression in CAR+ T-cells. (Figure 6B-C, 
Supplementary Figure S3).  After 10 days of culture (5 days after transduction), no 
differences were seen in the percentages of exhausted cells between the two CAR+ 
groups (Figure 5C), but by day 16 (11 days after transduction), the GD2-DAP10 
CAR+ population contained significantly fewer exhausted cells than the GD2-28- 
CAR+ population (Figure 6D).  This tendency was also seen at day 24 
(Supplementary Figure S3).. Moreover, comparison of frequencies of “activated” 
events, i.e. cells that express activation markers CD25 and/or CD69, indicated a 
tendency towards a more activated phenotype (CD69+/CD25+) in GD2-28- CAR+ 
T cells compared to GD2-DAP10 CAR+ T cells, in the absence of further 
antigenic stimulus (Supplementary Figure S5). Thus, whilst CAR expression appears 
to impart a degree of exhaustion, it appears that this effect is less pronounced when 
the GD2-DAP10 CAR is expressed compared to the GD2-28- CAR, perhaps related 
to lower levels of background activation in GD2-DAP10 CAR+ T cells. 
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Discussion 
On-target off-tumour toxicity is one of the major impediments to successful cancer 
immunotherapy. It is typically approached in two ways – either by avoiding antigens 
which may be expressed on healthy tissues, restricting antigen choice, or by 
accepting non-tumor antigen expression and the potentially severe toxicities that 
accompany it.  Examples of this approach include anti-CD19 and anti-CD20 
immunotherapies which have been used against lymphoid malignancies (Jackson et 
al., 2016; Batlevi et al., 2016).  The elimination of healthy CD19+ B-cells is 
considered to be an acceptable toxicity in this instance, as patients can be supported 
long-term with intravenous immunoglobulin infusions as required. Neurotoxicity 
associated with the CD19 CAR T cells is an emerging concern (Maude et al., 2014;  
Davila et al., 2014; Lee et al., 2015).   In other cases such as neuroblastoma targeted 
with anti-GD2 monoclonal antibodies, the toxicity is more severe with pain being 
experienced presumably secondary to engagement of GD2 expressed on peripheral 
nerve fibres. Fatal off target toxicity has also been reported using CAR T cells 
targeting EGFR (Morgan et al., 2010). The ability to differentiate between “X-on 
tumour” and “X-on healthy” would solve this problem; not only reducing toxicity but 
also making previously overlooked antigens available for targeting. 
 
Here, we have demonstrated that by providing supplementary DAP10 signals via a 
“co-stimulation only” CAR, V2+ T cell anti-neuroblastoma cytotoxicity can be 
induced.  Neuroblastoma and DAP10 were chosen for this model because of low 
background killing of neuroblastoma by unmanipulated V2+ T cells, and because 
of previously documented immune evasion of NKG2D/DAP10 signalling in this 
disease (Raffaghello et al., 2004). In tumor systems which do not evade killing 
through down-regulation of membrane bound or production of soluble NKG2D 
ligands, supplementing DAP10 signals to tumor-targeting T cells may not be of 
benefit.  Anti-tumor cytotoxicity is associated with production of IFN-, which is not 
produced by GD2-DAP10 CAR+ V2 when the CAR or the TCR are stimulated in 
isolation (Figures 2 and 3).  The lack of pro-inflammatory cytokine production in the 
absence of a second signal in the neuroblastoma model is consistent with our 
previously published findings which demonstrated the need to coat neuroblastoma 
cells with antibodies that sensitize to ADCC to generate an optimal IFN- response in 
V2 T cells (Fisher et al., 2014).  It is interesting however that the IFN- signal 
provided by concurrent TCR and “co-stimulation only” CAR stimulation is still lower 
than that induced by engagement of a second generation CAR with CD3-CD28, 
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suggesting that inclusion of other co-stimulatory molecules in the CAR design may 
be of benefit. In addition, future characterization of other co-stimulatory endodomains 
within the costimulation-only CAR architecture will explain if intracellular detection of 
TNF-α upon engagement of the GD2-DAP10 CAR only is due to the endodomain 
chosen here, i.e. DAP10, which has previously been associated with TNF-α 
production after NKG2D activation (Rincon-Orozco et al., 2005). 
 
We have demonstrated that the GD2-DAP10 CAR can induce V2+ T-cell 
cytotoxicity only against cell lines that engage both the TCR and the CAR, 
providing more precise control than conventional CD3-containing CARs which 
induce cytotoxicity in the presence of target antigen alone.  This precision of control 
is robust in cell-based and bead-based assays indicating mechanistic consistency.  
Unfortunately, due to the restriction of human GD2 expression to primary neurons, it 
is not feasible to perform cytotoxicity assays against healthy GD2+ cells. We have 
previously demonstrated that peripherally administered V2+ T cells will invade and 
kill subcutaneous neuroblastoma in a murine model (Fisher et al. 2016).  However, it 
would not be possible to generate a murine model of healthy neuronal tissue which 
would have any possibility of engaging the human V9V2 TCR due to the species- 
specificity of this interaction. The majority of T cells that penetrate epithelial 
surfaces are of non-V2+ subsets, which have greater antibody-independent anti-
tumor ability (Fisher et al., 2014) and therefore are less amenable to precise control.  
V2+ T cells are generally restricted to the bloodstream and are much less 
abundant in the tissue space. 
 
Adoptively transferred cells used in cancer immunotherapy must be able to survive in 
the host and mount a secondary expansion in response to their target antigen.  T-cell 
exhaustion due to over-stimulation or tonic CAR signalling can render a cellular 
immunotherapy short lived or ineffective (Long et al., 2015; Wherry and Kurachi, 
2015).  There is no sustained significant difference in the exhaustion phenotype of 
“co-stimulation only” CAR V2+ T cells and those transduced to express 
conventional second generation CARs, though there is a tendency towards a less 
exhausted phenotype.  Whilst GD2-DAP10 V2+ cells are able to produce IL-2 in 
response to simultaneous CD3 and CAR stimulation (Figure 3), the secondary 
expansion seen after re-challenge with target antigen expressing tumor cells is 
modest, suggesting that further stimulus may be required.  It would be perhaps unfair 
to compare the secondary expansion potential of V2 T cells with that of CAR 
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transduced T cells however, as the baseline dynamics of these cell types are 
different. New light will be shed on the applicability of γδT-cell subsets in future 
immunotherapy approaches as novel insights underpin the important role of specific 
tissues in modelling their local γδT-cell compartments (Di Marco Barros et al., 2016).  
 
By introducing a novel, more precise approach to cellular cancer immunotherapy, 
“co-stimulation only” CARs expressed in V2+ T cells present a choice.  V2+ T 
cells are less abundant, harder to expand and less well understood than T cells, 
but they offer a means of specifically targeting tumors without harming healthy 
antigen-positive cells.  The balance between force and precision of the anti-tumor 
response will depend on the context, but this approach at least offers an opportunity 
to target abundant and immunogenic molecules that were previously placed out-of-
bounds by toxicity. 
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Figure Legends 
 
Figure 1. Chimeric antigen receptor expressed in expanded gamma delta T 
lymphocytes enhances antigen specific cytotoxicity. (A) 2nd generation  anti-GD2 
Chimeric Antigen Receptor containing the CD3 and CD28 endodomains allows 
activation of T cells in the absence of TCR engagement. (B and C) 51Cr-release 
assay demonstrating cytotoxicity of V2+ T cells expressing an anti-GD2-28 CAR 
against GD2+ and GD2- neuroblastoma cell lines. In (B) antibody dependent 
cytotoxicity at E:T ratio of 10:1 was measured after coating the target cells with 
ch14.18/CHO anti-GD2 antibody or isotype control antibody (n=3 independent 
experiments). In (C) statistical differences shown for 10:1 E:T ratio Error bard 
indicate mean values ± SEM; **P<0.01, ****P<0.0001 after Bonferroni post-hoc 
analysis.  The bar chart on the right shows 10:1 E:T ratio with analysis by unpaired t-
test; n=3 independent donors for GD2-28- and untransduced T cells, n=6 for 
GD2-28- CAR+ T cells, n=14 for untransduced T cells. 
 
Figure 2. CAR-mediated co-stimulation is essential to allow functional 
activation of γδT cells upon TCR engagement.  (A) V2+ T cells are activated in 
an MHC independent manner, by indirectly sensing increased phosphoantigen levels 
on tumors through engagement of the TCR with cognate ligand.  Tumors evade T-
cell cytotoxicity by suppressing the co-stimulatory signals required. CARs containing 
costimulatory domains can bypass this evasion whilst retaining tumor specificity.  
Healthy tissues do not produce increased phosphoantigen levels so that the TCR is 
not engaged and the CAR alone is insufficient to provide full activation. (B) 
Schematic representation of the experimental design. Anti-CD3 antibodies coupled to 
the surface of beads were used to activate TCR (signal 1); anti-CAR (anti-Fc) 
antibodies activate the CAR (signal 2) through binding the CH2CH3 linker of the 
CAR.  (C) Representative dot plots of γδT-cell analysis by flow cytometry after 
incubation with beads labeled with anti-CD3 and/or anti-CAR antibodies. The binding 
and crosslinking of a second generation CAR is sufficient to allow full T-cell activation 
since both signal 1and 2 are provided by the CAR, i.e. by the CD3ζ chain and the 
CD28 endodomain, respectively. According to the co-stimulation only CAR concept 
the engagement of a CAR providing only signal 2, e.g. by a DAP10 endodomain, 
does not lead to γδT-cell activation. Only if signal 1, e.g. due to TCR activation, is 
provided in parallel γδT cells become activated and respond by functional changes, 
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e.g. IFN- production. (D) The engagement of a second generation CAR, i.e. GD2-
28-ζ, is sufficient to induce a profound production of pro-inflammatory IFN-γ by γδT 
cells. In contrast, γδT cells expressing a co-stimulation only CAR (GD2-DAP10) 
produce IFN-γ only upon both TCR and CAR engagement.  (E) No differences in 
TNF-α production were found for respective anti-CD3 and/or anti-CAR antibody-
stimulated γδ T cells expressing the GD2-DAP10 or the GD2-28-ζ CAR. (D, E) 
Bonferroni post-hoc analysis after 1-way ANOVA. Graphs display merged results 
from two independent experiments (n=4-6 independent donors). Error bars represent 
mean values ± SD. 
 
Figure 3. Cytokine secretion by GD2-DAP10 V2+ cells is dependent on CD3 
and CAR engagement. Cytokine production by V2+ T cells expressing GD2-
DAP10 or GD2-28- CARs following 23 h stimulation with antibody-coated beads 
engaging CD3, the CAR or both.  Non-transduced T cells denoted “no virus” are 
included for comparison, and CD3/CD28 bead stimulation was included as a positive 
control. Error bars indicate SEM of 3 independent donors. 
 
Figure 4. Vδ2+ γδT cells expressing GD2-DAP10 CARs kill GD2+ tumor cells. 
Specific killing of (A) Neuroblastoma line LAN-1  (n=14 independent donors for 
untransduced and (B) GD2+ Ewing sarcoma cell line TC-71 (n=3 independent 
donors) by GD2-DAP10 CAR+. (C) This effect is not seen against the GD2- 
neuroblastoma cell line SK-N-SH (n=3 independent donors). (D) The GD2-DAP10 
CAR does not function in αβT cells where signal 1 is absent indicating that the signal 
is restricted to the co-stimulatory pathway (n=3 independent donors for each 
subgroup). Frequencies are shown as mean ± SEM; significance by Bonferroni post-
hoc correction after 2-way ANOVA, with only E:T 10:1 annotated for clarity. 
 
Figure 5.  Target cells not engaging the  Vγ9Vδ2 are not killed by GD2-DAP10 
CAR  Vδ2+ γδT cells. (A) The murine colonic carcinoma cell line CT26 was 
transduced to express human GD2 and to derive the cell line CT26-GD2. Expression 
of GD2 was as homogenous as that detected for LAN-1. (B) 51Cr-release assay 
demonstrating the ability of αβT cells expressing the GD2-28-ζ CAR to kill CT26-GD2 
cells in an antigen specific manner.  Killing of wild-type CT26 and background killing 
by untransduced αβT cells is minimal (n=3 independent donors for each subgroup). 
(C) 51Cr-release assay demonstrating that Vδ2+ γδT cells expressing the GD2-28-ζ 
CAR kill CT26-GD2 cells in an antigen-specific manner even though CT26 does not 
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engage the Vδ2+ γδTCR, whereas Vδ2+ γδT cells expressing the GD2-DAP10 CAR 
do not (n=7 independent donors for each subgroup). A difference for killing of CT26 
target cells was also determined at E:T 10:1 using GD2-28-ζ CAR+ cells compared to 
GD2-DAP10 CAR+ cells (n=7 independent donors for each subgroup).  Frequencies 
are shown as mean ± SEM, with significance by Bonferroni post-hoc correction after 
2-way ANOVA,; only E:T 10:1 annotated for clarity. 
 
Figure 6. Expression of  GD2-DAP10 CAR  in Vδ2+ γδT cells leads to less 
exhaustion and activation marker expression than GD2-28-ζ CAR. (A) Vδ2+ T 
cells expressing the GD2-DAP10 CAR were transduced and then maintained in 
medium containing 100 IU/ml IL-2 for 3 weeks.  They were then washed thoroughly 
and co-cultured with irradiated GD2+ LAN-1 or GD2- SK-N-SH neuroblastoma cells in 
the absence of exogenous IL-2.  A combination of live-cell counting by Trypan Blue 
exclusion and FACS analysis for CAR+/Vδ2+ cells was used to determine fold change 
over a 3-week co-culture.  Only in the presence of GD2+ targets did the CAR+ cells 
mount a secondary expansion (n=3 independent donors, fold change compared by 
paired t-test at day 14 and day 20). (B) Gating to determine phenotype of CAR 
transduced T and T cells over prolonged culture in medium containing 100 IU/ml 
IL-2.  Transduction efficiencies as well as the expression of TIM-3 and PD-1 were 
assessed by flow cytometry at each time point. Note, that analysis of TIM-3 and PD-1 
expression for conventional αβ T cells was based on gating on Vδ2− events. Cells 
expressing TIM-3 and/or PD-1 were considered to have an “exhausted” phenotype. 
(C) After 10 days of culture (5 days after transduction) no significant differences were 
found by comparing the frequencies of exhausted events in all subgroups.   
Exhausted cells were defined as those expressing at least one of the exhaustion 
markers TIM-3 or PD-1. (D) At day 16 of culture (10 days after transduction) T or 
T cells expressing GD2-28- CARs were more exhausted than either untransduced 
T or T cells.  Furthermore, T cells expressing the GD2-28- car were 
significantly more exhausted than T cells expressing the GD2-DAP10 CAR.   As in 
(C), for the purposes of this analysis, cells were considered to be exhausted if they 
expressed TIM-3, PD-1 or both. (C) and (D) display combined results from two 
independent experiments (n=5 for γδT cells, n=6 for αβT cells) subjected to 
Bonferroni post-hoc analysis after 1-way ANOVA. Columns represent mean values ± 
SD. 
  
Supplementary Figure S1 Detection of CD3 and CAR expression using 
biotinylated primary antibodies. Human αβT cells were expanded using anti-CD3, 
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anti-CD28-coated beads. (A) Using flow cytometry, frequencies of cells staining 
positive for expression of CD3 or CAR were determined, using the human Fc derived 
CH2CH3 linker of the CAR as a target (shown: cells stained with anti-Fc-biotin and 
Streptavidin-PE).  (B) By staining T cells with anti-CD3-FITC antibody 97.8% of 
events were found to be CD3+. In comparison, 93.6% of CD3+ events were detected 
using Streptavidin-PE after staining of cells with anti-CD3-biotin. (C) To determine 
the frequency of CAR-expressing T cells the anti-CD34-APC antibody was used. 
73.5% of T cells were CAR+. By using anti-CAR-biotin and Streptavidin-PE 76.4% of 
events were found to express the CAR.   
 
Supplementary Figure S2 Efficient labeling of anti-biotin beads upon 
incubation with biotinylated antibodies and Streptavidin-PE.  (A) The specific 
loading of beads with biotinylated antibodies was detected by flow cytometry.  (B) 
First, beads were labeled with anti-CD3-biotin, anti-CAR-biotin or anti-CD3-biotin 
plus anti-CAR-biotin antibodies followed by incubation with Streptavidin-PE. (C) 
Overlays of histograms showing successful binding of antibodies by beads in 
comparison to controls. 
  
 
Supplementary Figure S3 γδT cells and αβT cells transduced to express GD2-
DAP10 or GD2-28-ζ CARs express significantly more PD-1 than untransduced 
γδT or αβT cells. At day 16, a reduced frequency of PD-1+ GD2-DAP10-expressing 
γδT cells was found compared to PD-1+ GD-28-ζ CAR-expressing γδT and αβT cells.  
For analysis 2-way ANOVA followed by Bonferroni post-hoc analysis was applied. 
The graph displays merged results from two independent experiments (n=5 for γδT 
cells, n=6 for αβT cells). Columns represent mean values ± SD.  
 
Supplementary Figure S4 Expression of TIM-3 and PD-1 by CAR-expressing T 
cells at day 24.  At day 24 of culture (19 days after transduction) of γδT or αβT cells 
the expression of TIM-3 and PD-1 were analyzed as a follow-up of day 10. A higher 
frequency of exhausted GD2-28-ζ CAR expressing γδT and αβ T cells was found in 
comparison to untransduced T cells in the GD2-DAP10 system. Graphs display 
merged results from two independent experiments (n=5 for γδT cells, n=6 for αβT 
cells) subjected to Bonferroni post-hoc analysis after 1-way ANOVA. Columns 
represent mean values ± SD, *P<0.05 after post hoc analysis.  
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Supplementary Figure S5:  Expression of CD25 and CD69 by CAR-expressing T 
cells in the course of expansion after transduction.  At day 10 and 18 after 
induction of γδT-cell expansion the expression of activation markers CD25 and CD69 
were analyzed. (A) No significant differences in frequencies of “activated” events, i.e. 
events positive for CD25 and/or CD69, were found for GD2-28-ζ CAR expressing 
γδT cells and GD2-28-ζ mock-transduced γδT cells in comparison to GD2-DAP10 
CAR γδT cells and GD2-DAP10 mock-transduced γδT cells. (B) Additionally, at day 
18 of γδT-cell expansion, no significant differences in frequencies of “activated” 
events were found comparing CAR-expressing γδT cells and mock-transduced γδT 
cells. Graphs display results from one experiment (n=4 at day 10, n=3 at day 18). 
Bonferroni post-hoc analysis was performed after 1-way ANOVA. Both the overall 
ANOVA and the post-hoc analysis showed no significant differences. Columns 
represent mean values ± SD.  
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